Startseite Kongressberichte & Archiv ASCO Annual Meeting 2017 ASCO Press Conferences 2017 ASCO Annual Meeting Presscast June 3 Part 2

2017 ASCO Annual Meeting Presscast June 3 Part 2

This presscast below has been produced by ASCO. According to the ASCO press release the following studies have been presented in the Saturday June 3 “News of the Day” Part 2 Briefing:

  • The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers (Abstract LBA2501)                                                                   (presscast presentation starts at min 30:30)                                                                                                             The autors conclude that Larotrectinib has demonstrated consistent and durable antitumor activity in TRK fusion cancers, across a wide range of ages and tumor types, and was well-tolerated. Larotrectinib could be the first targeted therapy developed in a tissue type-agnostic manner, and the first developed simultaneously in adults and pediatrics. Read the full release.
  • Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer (Abstract LBA11516)                                                            (presscast presentation starts at min 42:24)
    The autors conclude that This novel, high-intensity ctDNA assay enabled broad detection of genomic variants in plasma at high rates of concordance with corresponding tumor tissue, providing strong evidence for tumor-derivation of these signals. This study will inform development of a high-intensity sequencing approach for early cancer detection. Read the full release.
     
  • Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProfilER Study (Abstract LBA100)                                                                                 (presscast presentation starts at min 54:30)
    The autors conclude that In this series of 2490 cancer pts, CGH and NGS identified actionable alterations on 51% of pts, with treatment recommendation in 35%. Most patients treated derived benefit from the recommended MTT, but these represent a minority of the whole population screened Read the full release.